Discovery Expo in den USA>>>>Endovasc Ltd., Inc.<<<<!!! - 500 Beiträge pro Seite

[[KERN]Codex]

Hallo,
Mir ist ein Biotech Unternehmen ins Auge gesprungen und
nun habe ich zu diesem [(Endovasc WKN:919591)]
ein paar Informationen zusammengetragen:



Nun kommen wir zum wichtigsten Punkt:

In den United States findet derzeit eine Messe statt und zwar die sog. Discovery Expo!!
Jede Firma hofft durch diese Messe einen großen Bekanntheitsgrad zu erlangen um später aus
dem OTC Freiverkehr heraus an die Nasdaq zu gelangen.Ich denke, dass Endovasc eine große
Chance besitzt. Was das bedeutet, aus dem Freihandel raus / und in die Nasdag rein / ,kann
man sich letzten Endes denken. Diese Messe ist die größte ihrer Art in den USA und wird dieses
Jahr alle Rekorde sprengen!

Hier ein kurzer Englisher Text:

Attendees came because there is no other place to
meet the CEOs and CFOs of underdiscovered mid-
and small-cap companies face-to-face in just eight
hours. These are companies, under $300 million in
annual revenue, that have fallen off the financial radar
screen. This alone tends to make them undervalued.
The Pros use it as a resource. One Fund Manager
said, "I found four companies from the last expo that
I made money on. That`s why I keep coming back." A
stock club investment officer reported he discovered a
turnaround with only a 3 p/e multiple!
The Discovery Expos have many terrific investment
possibilities.

Ok da wird ja auf jeden Fall kräftig die Werbetrommel gedreht,
und ich Hoffe doch sehr das TV und Messe ( ab Gestern ) etwas
bewirken, damit auch andere Investoren auf diesen Wert aufmerksam
werden.

MONTGOMERY, Texas--(BUSINESS WIRE)--Oct. 13, 2000--Endovasc Ltd. Inc.
(OTCBB:ENDV) announced that the company will air on "Business World News"
on The Learning Channel as sponsored programming on Sunday, October 15, 2000
at 7:30 a.m. (check local listing). Interviews and brief descriptions of the company`s
research and development work and upcoming clinical trials will highlight Liprostin(TM),
as well as the company`s newly licensed angiogenic growth agent, nicotine receptor
agonist (NRA). If you have questions about the broadcast, please call Endovasc Ltd. Inc.
and not The Learning Channel. The sponsored programming will be rebroadcast in
major metropolitan cities on national Cable Networks and/or broadcast affiliates.

>>>>>>Below is the October schedule: <<<<<<


-- October 21/8:30 p.m., Channel 31/AT&T in San Francisco
-- October 22 & 23/7:00 p.m., AT&T cable in Chicago
-- October 26/9:00 p.m., Channel 3/Charter Comm. in Riverside, Calif.
-- October 30/6:30 p.m., Channel 23A/AT&T in San Jose, Calif.
----------------------------------------------------------------------------------------------------------------------------------------------
Zuerst einmal ein >>> Company Profile<<<

Endovasc Ltd., Inc. (OTCBB: ENDV)
15001 Walden Road, Suite 108, Montgomery, TX 77356
Tel: [phone] Fax: [phone]
Email: [e-mail] www.endovasc.com

Company Representatives:

Roy A. Robertson, vice President of Business Development
Barbara J. Richardson, Investor Relations

Primary Business:

Endovasc Ltd., Inc., a biopharmaceutical company, develops and markets products chiefly
for treatment of heart and vascular disease. Through its propri-etary liposomal drug delivery
technology, Endovasc’s primary product, Liprostin™, reduces the problem of restenosis
(new blockages) for stenting and angioplasty. This drug delivery method will also be combined
with products, such as Nicotine Receptor Agonist (NRA), a newly discovered growth agent
licensed exclusively to Endovasc to treat other life impeding diseases.

Market Overview:

The company’s goal is to become the leader of liposomal drug delivery technology in the
treatment of restenosis, and pioneer its use with NRA in biological bypass therapy alternatives,
as well as treatments for wound healing, skin grafting, and chronic leg pain. The American
Heart Association estimates 450,000 coronary artery bypass and 750,000 angioplasty
procedures this year. With estimated market size projections of $2 billion annually, Endovasc
projects $15-18 million sales revenues by 2002.

Financial Data:

Endovasc is currently entering into clinical trials. Therefore, revenue statistics are not available.
($ in millions, except per share data)
Qtr. End(Dec)----Revenue----Shares Issued----Shares Outstanding

1999---------------------0-------------- 10.7--------------------- 8.1
1998---------------------0---------------- 4.1--------------------- 4.1

Ich würde mich über weiter Informationen und über viele kommentare bezüglich Endovasc
sehr freuen!

...in zusammenarbeit mit menatwork00

Gruß Codex (bin ganz dick drin)!!

[[KERN]Codex]

Hallo,

Gibt es Meinungen zu diesem Wert oder bezüglich der Discovery Expo?

Gruß Codex

[[KERN]Codex]

Hallo,
gibt es Meinungen oder Kommentare zu Endovasc/Discovery Expo??

Gruß Codex

[menatwork00]

Hey codex,

kompliment - hast dir wirklich Mühe gegeben den Wert hier vorzustellen-schade das sich so wenige hier beteiligen-aber ich denke sehr wenige kennen diesen Wert und werden sich jetzt ein wenig damit beschäftigen-ich meine immer noch, das es sich kräftig lohnen wird.


Gruß MH

[[KERN]Codex]

...und up!

da tut sich heute ja net so viel, aber wir werden sehen...

Gruß Codex

[[KERN]Codex]

Hallo,

nachdem wir in den letzten Tagen nur eine Seitwärtsbewegung gesehen haben, denke
ich, dass es heute wieder nach oben gehen könnte!




Was meint ihr dazu?

Gruß Codex

[menatwork00]

Endovasc bewegt sich weiterhin seitwärts codex-aber immerhin schon 1,85 % gemacht. Der Wert wird langsam wachsen-bin natürlich etwas verwöhnt durch Antisoma-aber das ist ja auch nicht ganz normal, wie der Kurs explodiert.

[sagenhaft]

geht mal zu den suntraders (suntrade.de) die kennen den wert bestens

[[KERN]Codex]

Jo danke...mach ich!!

[[KERN]Codex]

Hallo,

Schade eigentlich, dass dieses Unternehmen so unbekannt scheint!
Gibt es denn noch investierte hier onBoard?
Würde mich über weitere Meinungen und Kommentare sehr freuen!

Gruß Codex

[meisterspieler]

Hi codex

wenn ich mit endv jemals erfolg haben sollte (und mich hat`s ganz schön gebeutelt die letzten 2 Monate) dann habe ich das deinem tipp zu verdanken. bin seit 2 wochen mit 8000 stck. investiert und hoffe jetzt auf einen glänzenden rebound. dass der boden von endv gefunden ist, kann man ja am chart hervorragend sehen. es kann m.e. nur noch nach oben gehen...

bei dieser gelegenheit möchte ich dich auf mein lieblingskind aufmerksam machen - dna print genomics. gib das kürzel dnap doch mal in die suchmaske ein und les dir die threads durch. vielleicht legst du dir auch noch wie ich dieses eisen ins feuer...

read you - meisterspieler

[[KERN]Codex]

Hallo,

@Meisterspieler
Ja ich denke genau wie du, dass der Boden bei ENDV gefunden wurde, aber nun
möchte ich nochmal auf die sehr hohen Tages Schwankungen aufmerksam machen,
was wir ja Gestern deutlich gesehen haben!!
Also Endovasc ist nur etwas für Leute, die starke Nerven haben...hehe
Danke für den Tipp...werde mir Dna Print Genomics mal näher betrachten!

Gruß Codex

[menatwork00]

hallo codex,

hattest du den gestern abend strake nerven ???? :-))))))



Gruß men

NS. siehste alles wieder im grünen Bereich

[[KERN]Codex]

Hey men!

Naja...ich gebs zu: In bischen hat mein Herz doch schon geflattert, aber nun ist alles
wieder gut..*g
Und es wird besser werde, spätestens wenn wir wieder nen Megahype kriegen und
die AMIS alles kaufen was nur nach Biotech riecht!!
Wir haben ja gesehen wie ENDV im März performt hat..hehe

Gruß Codex

[meisterspieler]

hallo codex

gerade beim recherchieren entdeckt, dass du auch im trinity thread vertreten bist. da haben wir ja schon wieder die selben aktien. ich habe vor ein paar tagen glück gehabt und mit einem abstauberlimit von 3,1 2000 stck. an land gezogen, d.h., natürlich nur, wenn der kurs nicht noch einmal zurückkommt, was leider wahrscheinlich ist. mich nervt diese trading range zwischen 3 und 4 langsam.

zu endovasc: ich habe seit langer zeit endlich die courage, meinen kostolany traum wahr zu machen, d.h. endv 2 jahre liegen zu lassen und nicht jeden tag den kurs zu verfolgen. zumindest bisher ist es mir gelungen...naja, ab und zu die postings lesen, das ist schon drin. aber der kurs in usa bleibt tabu.

was hast du sonst noch für papiere? ich antisoma - bisher eine traumperformance, und ich glaube sie geht weiter. habe zumindest ein super gefühl.

hinzu kommen viele abstauberlimits - xenova beispielsweise, oder id biomedical(hier droht u.u. eine sks formation, da heißt es zuschlagen...)

tschüsikowsky

[[KERN]Codex]

Hallo,

@meisterspieler
Der Verlauf von trinity ärgert mich auch etwas, aber so scharf sehe ich das nicht, nach dem
Motto "Die werde sich verdoppeln, dauert nur" ...hehe
Bei Endv denke ich genauso wie du, einfach liegen lassen und abwarten!!
Sonst habe ich noch Mologen, Antisoma, Xoma, Intel, Commerce One, Sun, HP und Nortel!!

Gruß Codex

[menatwork00]

@ codex,
@ meister glanz,

habe heute gerade diese e-mail von endovasc erhalten:

Date: Tue, 7 Nov 2000 11:40:16 -0800 (PST)
From: [e-mail]
To: [e-mail]
Subject: TV Schedule

Following is the TV schedule for Business World News Spotlight on Endovasc:
Monday, November 6 6:30pm Channel 31/COX Cable (Irvine, CA)
Monday, November 20 6:30pm Channel 31/COX Cable (Orange County, CA)
Wednesday, November 22 8:30pm Channel 47/AT&T (San Francisco,CA)
Friday, November 24 7:00pm Channel 26/AT&T (Oakland, CA)
Monday, November 27 6:30pm Channel 31/COX Cable (Irvine,CA)

[[KERN]Codex]

Hehe...das dürfte sich doch im Kurs wiederspiegeln...mehr sag
dazu nicht!

Gruß Codex

[[KERN]Codex]

hallo,

Wenn man Endovasc die letzten Wochen betrachtet hat, konnte man eine
überaus deutliche Bodenbildung im Bereich der 0,50 Dollar erkennen !!
Hier ein Chart der letzten Monate:



Hier der Chart der letzten beiden Wochen:


Nochmals der Langfristchart, um zu sehen was bei dem Biotech Hype im März
möglich war und in einem geringerem Maße auch wieder möglich ist, denke ich!



Gruß Codex

[menatwork00]

hallo Codex,

also eins muss ich endovasc lassen, e-mail´s die die Firma an
mich schickt-das hat doch seltenheitswert-immer aktuell und direkt von endovasc-muss da wohl im Verteiler drin sein,
nach meiner letzten Anfrage:

Date: Tue, 14 Nov 2000 14:45:21 -0800 (PST)
From: [e-mail]
To: [e-mail]
Subject: Press release


FOR NATIONAL RELEASE: WEDNESDAY, NOVEMBER 15, 2000; 8:30 AM EST

LIPROSTINT CLINICAL TRIALS TO BEGIN FOLLOWING SUCCESSFUL FILING OF
INDICATION FOR NEW DRUG WITH FOOD AND DRUG ADMINISTRATION
Montgomery, Texas (November 15, 2000) - Endovasc Ltd. Inc. (OTC BB:ENDV)
announced that the company has successfully completed final review by the
Food and Drug Administration of Endovasc`s IND (Indication for New Drug)
application for LiprostinT, a drug for the treatment of critical limb
ischemia (CLI), and that clinical trials are ready to begin.

LiprostinT Phase I and II clinical trials for the treatment of CLI, a
condition that can be caused by diseases such as heart disease and diabetes
and can lead to gangrene and amputation, particularly of the legs, will be
conducted under the direction of Dr. Richard W. Smalling of the University
of Texas Health Science Center in Houston. "We expect to move forward
quickly in the completion of these two phases to ensure safety and determine
correct dosing," stated Ms. Jenna Tagliaferri, Endovasc`s Director of
Regulatory Affairs. "Clinical sites for Phase III trials are being
identified."

Endovasc developed LiprostinT using the company`s liposome drug delivery
technology to encapsulate Prostaglandin E-1 (PGE-1), a well-known potent
vasodilator, platelet-inhibitor and anti-thrombotic, which is highly
effective in the prevention of vascular reblockage. Physicians know the
positive effects of PGE-1; and now through Endovasc`s liposomal technology
which will time release and site deliver PGE-1, desired results in
preventing reclosure can be accomplished.

Critical Limb Ischemia, an advanced form of peripheral artery disease,
occurs when the blood circulation in limbs, particularly the legs, becomes
so inadequate that they`re in danger of gangrene and amputation. According
to estimates, as much as 15 percent of the U.S. population over age 50
suffers from some form of peripheral artery disease. Unrelieved
limb-threatening ischemia can lead to, at the least, a partial amputation of
the diseased limb. Bypass grafting is the most common surgical alternative
for these patients; however, surgical intervention carries an increased risk
of other complications, including mortality. Endovasc`s LiprostinT delivers
PGE-1 to targeted parts of the body without the increased risks associated
with today`s surgical procedures. "Our goal is to improve the quality of
life for many facing limb amputation," stated Dr. David Summers, Chairman
and CEO.

Endovasc Ltd., Inc. is a biopharmaceutical/biotechnology company pioneering
liposomal drug delivery technology. The company`s products and processes are
covered by patents and trade secrets for competing in a multi-billion dollar
market. In February 2000, the company obtained worldwide exclusive license
for a newly discovered angiogenesis agent, nicotine receptor agonist (NRA),
a potent "angiogenic" growth agent that stimulates the growth of new blood
vessels in strategic areas of the body. NRA opens the door to a multitude
of therapeutic possibilities including vascular disease, neurological
disorders, such as Alzheimer`s and Parkinson`s and in the treatment of
tumors and cancer.

The foregoing statements are made under the "Safe Harbor" Private Securities
Litigation Reform Act of 1995 and may contain forward-looking statements
that involve risks and uncertainties that may not be evident at the time of
this release.
For more information about Endovasc Ltd., Inc., contact:

Barbara Richardson
Endovasc Ltd., Inc., 15001 Walden Road, Suite 108, Montgomery, TX 77356
Phone: [phone]: Fax: [phone]
email: [e-mail]; Or visit our web site: www.endovasc.com

Dick Kosmicki or Matt Swetonic
The Dilenschneider Group, Inc, 200 Park Ave. 26th Floor, New York, NY 10166
[phone]: Fax: [phone]
email: [e-mail] (or) [e-mail]


Gruß men

[[KERN]Codex]

Hallo,
wenn was von diesem Text wirklich interessant ist dann folgende
passage:

Endovasc Ltd., Inc. is a biopharmaceutical/biotechnology company pioneering
liposomal drug delivery technology. The company`s products and processes are
covered by patents and trade secrets for competing in a multi-billion dollar
market. In February 2000, the company obtained worldwide exclusive license
for a newly discovered angiogenesis agent, nicotine receptor agonist (NRA),
a potent "angiogenic" growth agent that stimulates the growth of new blood
vessels in strategic areas of the body. NRA opens the door to a multitude
of therapeutic possibilities including vascular disease, neurological
disorders, such as Alzheimer`s and Parkinson`s and in the treatment of
tumors and cancer.

Ich denke, dass könnt ihr euch selbsd zusammen reimen, denn so schweres
English ist das ja nicht!!

Gruß Codex

[meisterspieler]

hallo codex

jetzt habe ich mich doch hinreißen lassen und nachgeschaut.
was glaubst du ist los? nur eine bullishe divergenz mit anstehendem bounce oder noch tiefere kurse...
bitte poste mir infos - ich hab nicht soviel zeit zur recherche momentan.

thanx

[[KERN]Codex]

hallo meisterspieler!!

bisd du in ENDV investiert oder hasd du es vor?
Endovasc ist in letzter Zeit ziemlich volatil geworden, da ergeben sich zum Beispiel im Laufe eines Tages Spannen von über 50%...also wenn du in ENDV investieren möchtest, dann würde ich ein Abstauberlimit bei 0,21 setzen!! Mit ein wenig Glück sindse dann im Laufe des Tages über 0,30...was wir die letzten tage schon oft gesehen haben!!

Gruß Codex

P.S. News vom Unternehmen gibbet derzeit nicht...

[menatwork00]

Endovasc verkündete vor einigen tagen, daß Forscher von der Stanford-Hochschule für Medizin demnächst neue Daten herausgeben werden, die auf die Rolle des Nikotins hinweisen, die es auf das Wachstum neuer Blutgefässe hat.

The presentation, entitled
"Nicotine Increases Peripheral Conductance After Femoral Artery Occlusion,`` will be presented at the Scientific Conference on Therapeutic Angiogenesis and Myocardial Laser Revascularization Conference, sponsored by the American Heart Association, January 24 to 27. It will be delivered by Christopher Heeschen, M.D., of Stanford University. Dr. Heeschen, with Associate Professor John Cooke, M.D., Ph.D., in Stanford`s Vascular Biology Laboratory, discovered the blood vessel-growing effects of low-dose nicotine last fall.


Gruss men

[meisterspieler]

hallo codex (wie kommst du eigentlich auf diesen namen?)

halte momentan 10000 endv (kk.47)und hoffe, dass der letzte upmove nicht ein luftholen war, um noch weiter abzutauchen.
das ist schon beängstigend, was momentan abläuft.
wie weit kann eine endv noch fallen, oder eine xoma, trinity oder antisoma. wo stehen die in 1-2 jahren?
gibt`s diese firmen dann noch - oder sind wir bis dorthin reich? ich weiß es nicht. ich weiß nur, dass ich kurz davor bin alles zu verkaufen...
hast du dir mal dnap angeschaut? in die setz ich momentan meine hoffnung...

gesundes neues jahrtausend wünscht
meisterspieler

[meisterspieler]

und nicht zu vergessen trinity - das war schon ein schock.
ob die auch noch weiter fallen? shit, ich bin mir absolut unsicher zur zeit - alles nur minuspositionen, das nervt ganz schön

[[KERN]Codex]

hallo meisterspieler!!!

tja...ich sitz auch auf verlusten!!!

Bei Trinity bin ich zu 3,15€ raus und zu 2,58€ wieder rein...momentan leicht im MINUS!!

Bei ENDV habe ich auch 50% verlust...das is einfach nur ZOCK fuer die meisten, wenn ich mir so die Intraday charts (täglich) anschauhe...die sind halt irre volatil!!!
Am besten du setzt ein Verkaufslimit, wenn du unsicher bist!!
Dieses sollte aber weit (+10%-20%) über dem aktuellen kurs sitzen->> gerade wegen den tagesschwankungen!!

An deiner Stelle würde ich zum heutigen Zeitpunkt nicht alles verkaufen...lieber abwarten, denn so stark sind deine Titel ja heute nicht gefallen!!

gruß Codex

[[KERN]Codex]

hallo

na das geht doch schon ganz gut los im neuen Jahr (gestern +18%) und heute schon +2% ...ENDV wird uns noch viel freude bereiten!!



mal sehen wie sich endv heute entwickelt?!

gruß Codex...ich bleibe auf jeden fall investiert!

[meisterspieler]

ich habe mich entschieden, auch weiterhin in endv investiert zu bleiben.
jetzt noch raus, wäre quatsch, denn ich habe zeit.
außerdem hab ich an der otc eines gelernt: wenn die techn. oder fund. gegenreaktion kommt, dann gewaltig - und zwar an einem tag und in einer einzigen stunde...
das müsste uns zumindest wieder in die nähe unseres einstandes bringen und wenns auch erst in 6 wochen so weit ist.

haltet die ohren steif

[meisterspieler]

...und außerdem träume ich gerne - in drei jahren endv bei 5 Dollar...das wär doch was!

[menatwork00]

hallo ihr beiden,

habt ihr euch mal die Volume der letzten Tage angeschaut im Vergleich zum letzten Quartal in 2000.


Die Volume haben sich teilweise verzehnfacht-also ich bleibe auch investiert.

gruss men

[[KERN]Codex]

hallo menatwork

...jo habe ich mir auch gerad mal angeschaut....ist mir vorher noch garnet aufgefallen!


gruß Codex

[menatwork00]

Codex was ist bei Endovasc los !!!!!


Stückzahl bis jetzt 268.500 !!!!!

da wird ganz massiv gekauft die letzten Tage.

Im November waren wir froh wenn wir mal die 10.000 erreicht haben und was ist jetzt ???


Außerdem ist sehr schön zu erkennen das die Käufe deutlich überwiegen-da tut sich massiv etwas.

Gruss men

[menatwork00]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]

[menatwork00]

Na das klingt ja mal wieder sehr gut, schätze daher sind die Stückzahlen auch wieder höher gegangen!!

Endovasc Highlights New Findings On Nicotine Cardiovascular Treatment

Stanford Researchers to Present New Data At American Heart Association Meeting in January 2001


MONTGOMERY, Texas--(BW HealthWire)--Dec. 27, 2000--Endovasc Ltd. Inc. (OTCBB:ENDV - news) today announced that investigators from the Stanford University School of Medicine will present new data next month on nicotine`s role promoting the growth of new blood vessels.

The presentation, entitled "Nicotine Increases Peripheral Conductance After Femoral Artery Occlusion," will be presented at the Scientific Conference on Therapeutic Angiogenesis and Myocardial Laser Revascularization Conference, sponsored by the American Heart Association, January 24 to 27. It will be delivered by Christopher Heeschen, M.D., of Stanford University. Dr. Heeschen, with Associate Professor John Cooke, M.D., Ph.D., in Stanford`s Vascular Biology Laboratory, discovered the blood vessel-growing effects of low-dose nicotine last fall.

Stanford`s research on NRA`s impact on angiogenesis in an ischemic limb model on mice was presented at the American College of Cardiology in Anaheim, Calif. in March and at the European Cardiology Convention in Amsterdam in August. The research showed nicotine`s effect on new blood vessel growth in ischemic or blood-starved tissues was greater than all other known growth factors.

"This new data continues the progress in testing the viability of nicotine receptor agonist (NRA) as a potential treatment for the therapeutic growth of new blood vessels," said Dr. David P. Summers, Ph.D., chairman and CEO of Endovasc. "The results continue to be very promising."

Endovasc, which sponsored Stanford`s research, holds exclusive worldwide rights to Stanford`s patented process for using NRA to spur new blood vessel growth. The Company is estimating the market for such medicine as being over $300 million per year.

Endovasc Ltd. Inc. is a biopharmaceutical company specializing in the development and manufacturing of drug delivery technology. The company develops liposomal encapsulations of drugs that have already shown safety and efficacy. In the liposome form, dosage and time-release of the drugs can be controlled and time-released, for the treatment of vascular disease of the heart, limbs and clinical areas of the circulatory system. The company`s products and processes are covered by patent and trade secrets for competing in a $2 billion market, and it has recently met all SEC reporting requirements to be listed on the NASD OTC Bulletin Board.

Gruss men

[menatwork00]

hallo codex,

wenn ich mich heute mal auf comdirect verlassen kann, dann sind bisher bei Endovasc heute 85.200 Stück gehandelt wurden- gestern waren es sogar 122.000 Stück.

Im November 99 haben wir immer gehofft das die 10.000 mal überschritten wird-ich denke das passiert in den letzten Wochen reichlich.

Ich wette das wir noch reichlich ins Plus gehen werden und somit noch viel Spass mit unserem Wert haben werden.


Gruss men

[spidermonster]

Neues zu Endovasc
ENDOVASC ANNOUNCES DEVELOPMENT OF "SLOW RELEASE"
NICOTINE LIPOSOME FOR ANGIOGENESIS-NEW BLOOD VESSEL GROWTH AROUND BLOCKED
ARTERIES

MONTGOMERY, Texas-January 9, 2001. Endovasc Ltd., Inc. (OTCBB:ENDV) today
announced that the company`s collaboration with Hermes BioSciences, Inc. of
South San Francisco, has successfully produced a timed release, nicotine
liposome. Low dose levels of nicotine have demonstrated extraordinary
results in stimulating growth of new blood vessels that produce a biological
by-pass around blocked arteries and blood vessels.

Developed during the past year for its potential use in treatment of blood
and oxygen starved ischemic tissues, this liposome provides a 3 to 4 day
release of controlled levels of nicotine needed to initiate the angiogenic
or new vessel growth cascade that stimulates the body`s natural re-growth
process.

Chairman of Endovasc Ltd., Inc., Dr. David Summers said, "We are very
pleased with the results of our year-long collaboration with Hermes
BioSciences, Inc. They performed a thorough analysis of our needs and built
an array of liposomes for our selection of the best liposome for our
nicotine molecule, achieving the release characteristics we needed."

Hermes BioSciences, Inc. is a biopharmaceutical company dedicated to the
development of targeted drug/gene delivery systems and advanced
pharmaceutical formulations using liposome and nanoparticle technologies.

Poor blood vascular circulation is a major problem world-wide. Estimates of
the number of patients suffering from this disease, known as "hardening of
the arteries" range from 200 to 300 million. In severe cases, open heart
surgery, arterial bypass or, angioplasty are the only medical treatments
available.

Endovasc has successfully demonstrated in both mouse and rabbit models that
nicotine initiates the growth of new blood vessels around blockages. New
data on the results from the rabbit model will be presented at the AHA
Scientific Conference on Therapeutic Angiogenisis and Myocardial Laser
Revascularization in Sante Fe, January 24 through 27. Phase II human
clinical trials are set to commence March-April in Italy.

Endovasc Ltd., Inc., is a biopharmaceutical/biotech company pioneering
liposomal drug delivery and other cardiovascular treatment technologies,
including the use of nicotine to bring about angiogenesis. The Company`s
products and processes are covered by patents and trade secrets and
licensing agreements for competing in a multi-billion dollar market.

The aforementioned statements are made under the "Safe Harbor" Private
Securities Litigation Reform Act of 1995 and may contain forward-looking
statements that involve risks and uncertainties that may not be evident at
the time of this release.

Hoffentlich geht`s so weiter

Tschüss

[[KERN]Codex]

jo men

so langsam fängt der spass bei endv erst richtig an....hehe
die volumina sind schon extrem hoch und ziemlich konstant...der KURS steigt...sieht auch gut aus!!

gruß Codex

[menatwork00]

Endovasc Highlights New Findings On Nicotine Cardiovascular Treatment

Stanford Researchers to Present New Data At American Heart Association Meeting in January 2001


MONTGOMERY, Texas--(BW HealthWire)--Dec. 27, 2000--Endovasc Ltd. Inc. (OTCBB:ENDV - news) today announced that investigators from the Stanford University School of Medicine will present new data next month on nicotine`s role promoting the growth of new blood vessels.

The presentation, entitled "Nicotine Increases Peripheral Conductance After Femoral Artery Occlusion," will be presented at the Scientific Conference on Therapeutic Angiogenesis and Myocardial Laser Revascularization Conference, sponsored by the American Heart Association, January 24 to 27. It will be delivered by Christopher Heeschen, M.D., of Stanford University. Dr. Heeschen, with Associate Professor John Cooke, M.D., Ph.D., in Stanford`s Vascular Biology Laboratory, discovered the blood vessel-growing effects of low-dose nicotine last fall.

Stanford`s research on NRA`s impact on angiogenesis in an ischemic limb model on mice was presented at the American College of Cardiology in Anaheim, Calif. in March and at the European Cardiology Convention in Amsterdam in August. The research showed nicotine`s effect on new blood vessel growth in ischemic or blood-starved tissues was greater than all other known growth factors.

"This new data continues the progress in testing the viability of nicotine receptor agonist (NRA) as a potential treatment for the therapeutic growth of new blood vessels," said Dr. David P. Summers, Ph.D., chairman and CEO of Endovasc. "The results continue to be very promising."

Endovasc, which sponsored Stanford`s research, holds exclusive worldwide rights to Stanford`s patented process for using NRA to spur new blood vessel growth. The Company is estimating the market for such medicine as being over $300 million per year.

Endovasc Ltd. Inc. is a biopharmaceutical company specializing in the development and manufacturing of drug delivery technology. The company develops liposomal encapsulations of drugs that have already shown safety and efficacy. In the liposome form, dosage and time-release of the drugs can be controlled and time-released, for the treatment of vascular disease of the heart, limbs and clinical areas of the circulatory system. The company`s products and processes are covered by patent and trade secrets for competing in a $2 billion market, and it has recently met all SEC reporting requirements to be listed on the NASD OTC Bulletin Board.


Und Stückzahlen ( laut comdirect ) gestern 306.900
bin mal gespannt wie der Wert nachher an der OTC eröffnet.

Gruss men

[menatwork00]

@ codex,

hey heute haben wir wieder 12 % Plus bei endovasc und schau dir mal den chart an der läuft wieder deutlich in Richtung 0,30 -sehr gut

gruss men

[[KERN]Codex]

WOW ganze 5 Leute interessieren sich fuer ENDOVASC...lol

ja men läuft gut (allgemein) heute...siehe PM3, Xoma, usw.

gruß Codex

[menatwork00]

Da wird über kurz oder lang auch bei uns mehr interessieren
sein, da bin ich mir sicher-wie war der Satz doch gleich?

"Wer zu spät kommt den bestraft das Leben"

mich begeistern die täglichen hohen Stückzahlen, schau dir mal den Langfristchart an wo das ATH war und dazu die Stückzahlen.

Gruss men

[meisterspieler]

bin zwar kein ausgesprochener chartist, aber lineal anlegen gehört bei mir dazu...und siehe da, endv zeigt einen ausbruch aus dem abwärtstrend an - hoffentlich bleibts nicht nur bei dem versuch.
dennoch: endv bleibt ein exotischer wert, zumindest in unseren breiten und vielleicht nicht nur hier. ich meine, ein 98%iger Kursverfall spricht seine eigene sprache.
das ist ja härter als seinerzeit adelong.
ich hoffe nur, wir werden jetzt entdeckt. die stückzahlen sind schon ganz gut.
bin zuversichtlich und bleibe weiterhin dabei.(irgendetwas mach ich trotzdem falsch. bei 17 cent hab ich an verkaufen gedacht und jetzt ans kaufen...hihi)

[[KERN]Codex]

...freut mich meisterspieler!!
Echt n super tag heute...alles im plus!!
Endv scheint immer besser zu laufen!!

gruß Codex

[menatwork00]

hallo ihr beiden,

endovasc hat gestern mit 21,43 im plus geschlossen, Stückzahlen mal wieder deutlich ( über 400.000 )

gruss men

[meisterspieler]

laut bloomberg hat endv gestern mit 0.34 geschlossen, höchststände sogar bei 0.36
konnt mich nicht beherrschen und hab noch mal zugelangt.
10000 stck zu 0.28
war das ein schnäppchen? ich kann es nur hoffen.
habe jetzt 20000 stck. wow!
das wären dann ja bei einem kurs von 1 dollar... oder nein, sagen wir mal 2 dollar, oder 3?
halt, jetzt nur nicht gierig werden...(ich würde mittlerweile schon jubeln beim rückkehr meines einstandspreises - 0.52. ich bin wirklich bescheiden geworden...)

[[KERN]Codex]

der chart liefert ein deutliches kaufsignal...



..genau wie der MACD!!

gruß Codex

P.S. bloß nicht zu euphorisch werden!!!!

[[KERN]Codex]

momentan befinden wir uns bei 0,36 dollar
schon wieder ein plus von knapp 6%

gruß Codex

...läuft zwar heute nicht so gut ,aber bei endv is alles super!

[EUWE]

Aktuelle Turnaroundanalyse + Ergebnisse Liprostin Phase 1


WE ARE -- OTCNetStocks.com

Wednesday, January 24, 2001
In This Issue


ENDOVASC (OTC BB: ENDV) Recent price $0.37

Why is this the Turnaround Stock for 2001? Three words

Management Technology Fiscal Responsibility

Management is strong, experienced, passionate, realistic and long-term.

Technology They have set out to do a number of remarkable things that have to potential to dramatically improve the quality of life for many, many people worldwide.

Fiscal Responsibility Management has not bled the company dry. By maintaining a tight control over cash and shares, ENDV has not suffered the dilutive effect that many OTC BB biotechs have

Beyond that

Endovasc is an exciting young biotechnology company that in the first quarter of 2000 was trading around $10 - $12.00. The company is pioneering what is known as liposomal drug delivery technology. Patents and trade secrets cover the companys products and processes for competing in a multi-billion dollar market. In February 2000, the company obtained worldwide exclusive license for a newly discovered angiogenesis agent, nicotine receptor agonist (NRA), a potent "angiogenic" growth agent that stimulates the growth of new blood vessels in strategic areas of the body. NRA opens the door to a multitude of therapeutic possibilities including vascular disease, neurological disorders, such as Alzheimer`s and Parkinson`s and in the treatment of tumors and cancer.

While that can be a mouthful basically, the company is moving through the FDA Clinical Trial process with Liprostin(TM), a drug for the treatment of critical limb ischemia (CLI), a condition that can be caused by diseases such as heart disease and diabetes and can lead to gangrene and amputation, particularly of the legs. Again, a mouthfull so what is the potential market you ask? Well according to estimates, as much as 15 percent of the U.S. population over age 50 suffers from some form of peripheral artery disease representing a 60 70 Billion dollar market. It is the intention of Endovasc to grab a piece of this huge pie.

In addition the company has recently received a well-deserved capital infusion to fund these trails and push the business plan forward. We encourage our readers to dig into this company further. We have just conducted another interview with Dr. Sommers that provides tremendous insight into the company and what they are doing, along with several links to assist you in your due diligence. We have also included them here for you.

Company name: Endovasc
Symbol: ENDV
15001 Walden Road Suite 201 Montgomery, TX 77356
Phone: [phone] Fax: [phone]
Shares Outstanding - 12,800,000 - according to Marketguide.com
Estimated Float - 8,000,000 - according to company sources
SEC Filings
http://www.10kwizard.com/fil_list.asp?cik=1040415&alld=ON&g=…

=====================================================================================================================================================

Tuesday January 16, 8:31 am Eastern Time

Press Release

Endovasc Announces the Successful Completion of Phase I Human Trials and Enters
Phase II for Liprostin

MONTGOMERY, Texas--(BW HealthWire)--Jan. 16, 2001--Endovasc Ltd. Inc. (OTCBB:ENDV - news) today announced
the successful completion of the Phase I trials for its patented drug Liprostin(TM). Healthy volunteers were the subjects for the ``dose
tolerance`` tests, conducted by Dr. Dennis A. Ruff at his clinic in San Antonio.

Dr. Ruff and his staff have been part of 250 clinical trials, and Dr. Ruff has been principal investigator on studies covering
hypertension, diabetes, OA, CHF, CAD, AFIB and erosive esophagitis, to name just a few. Dr. Ruff said, ``Liprostin(TM) was well
tolerated and even at maximum tolerated dose (MTD) levels caused few side effects, all of which were minimal and very short term.``

In a statement regarding the MTD determined by these tests, Dr. David P. Summers, Ph.D., chairman and CEO of Endovasc, said, ``This
clears the way for Endovasc to take the next major step of taking Liprostin(TM) forward into Phase II trials. Phase II will treat
patients who have critical limb ischemia and will be conducted by Dr. Richard W. Smalling of the University of Texas Center for
Cardiovascular Medicine in Houston.

Liposomal Prostaglandin E1, (PGE-1) known by its trademark, Liprostin(TM), is a patented drug and delivery system (liposomes), which can
be delivered to specific vascular areas for treatment of occlusive vascular disease and other indications. Liprostin(TM), delivered to
angioplasty sites, could greatly reduce restenosis or new blockage and can save the healthcare system billions of dollars, and reduce
the number of patients experiencing repeat angioplasty procedures.

Endovasc Ltd. Inc. is a high technology biopharmaceutical/biotech company pioneering liposomal drug delivery and other cardiovascular
treatment technologies, including the use of nicotine to bring about angiogenesis. These medical products may significantly impact the
cardiology, radiology and oncology markets. ``We are very excited about the continued success of Liprostin(TM) and look forward to the
day everyone gets to benefit from our research and development,`` said Dr. Summers.

The foregoing statements are made under the `Safe Harbor` Private Securities Litigation Reform Act of 1995 and may contain
forward-looking statements that involve risks and uncertainties that may not be evident at the time of this release.


Cheers !

EUWE

[[KERN]Codex]

thx EUWE!!

bist du auch investiert?

gruß Codex

[appaloosas]

hallo bin neu hier,wie gehts die nächsten wochen eurer meinung nach weiter ??
sollte ich drin bleiben??

[[KERN]Codex]

hallo appaloosas!

wo bist du den eingestiegen?
ich denke, dass es weiter nach oben gehen wird, da der aufwärts trend noch ungebrochen ist und auch kein anzeichen dafuer vorhanden ist. außerdem bildet der MACD ein kaufsignal aus!

gruß Codex

P.S. also bleib dabei (mein KK is 0,53)

[[KERN]Codex]

hehe

wie men und ich schon lange predigen...lol

heute +12%

diese woche scheint es weiter zu gehen!

gruß Codex

[spidermonster]

Hier sind die letzten Nachrichten zu endovasc
Hört sich sehr gut an


For Release Thursday, February 1, 2001, 8:30 A.M. EST

ENDOVASC REPORTS NICOTINE CONTINUES TO
DEMONSTRATE EXTRAORDINARY ANGIOGENESIS

MONTGOMERY, Texas- (BUSINESS WIRE)-February 1, 2001-Endovasc Ltd. Inc.
(OTCBB:ENDV) today announced results of its further animal studies of
nicotine receptor agonist (NRA) in rabbit hind-limb ischemia model for
critical limb ischemia. The paper, "Nicotine Increases Peripheral
Conductance After Femoral Artery Occlusion" was presented by Christopher
Heeschen, M.D. at the American Heart Association (AHA) Scientific Conference
on Therapeutic Angiogenesis and Myocardial Laser Revascularization in Santa
Fe, New Mexico. Dr. Heeschen showed results of rabbit studies conducted in
Associate Professor John Cooke`s Vascular Biology Laboratory at Stanford
University School of Medicine. The primary efficacy end point, increased
capillary density, angiographically demonstratable collaterization and
improved perfusion to the ischemic limb, which was documented by a superior
calf blood ratio and improved blood flow in the ischemic at maximal
vasodilation.

Dr. Thomas Quertermous, the William G. Irwin Professor of Cardiovascular
Medicine and Molecular Cardiology at Stanford University who was also
presenting at the conference additional data on stem cell and progenitor
endothelial cell recruitment to the ischemic zones by nicotine remarked, "We
have never seen anything like this!" Stem cells and progenitor endothelial
cells are utilized by the body to form angioblasts that cause vascular
sprouting.

Endovasc said its nicotine receptor agonist trial in the hind-limb ischemia
rabbit model was the acid test for proof of concept that nicotine produces
remarkable angiogenesis in critical ischemic limb. The Company previously
observed extraordinary angiogenic response in the mouse model that encourage
d higher species experimentation. "These results are better than anything
yet seen," said Dr. David P. Summers, Company Chairman and CEO. "Compared
to Vascular Endothelial Growth Factor (VEGF) in the same model, the results
were significantly better." (see J. Clin. Invest. Vol. 93 (Feb. 1994,
662-670). NRA produced greater capillary density, 4.1 times control group
vs. VEGF 2.5 times control group. Calf blood pressure ratio for nicotine
was 97 vs. control 68 at day 28 (P=0.008) compared to VEGF (75 vs. control
48 P=<0.05) at day 40. "Angiographic evidence although subjective to
interpretation, demonstrated robust collateral development >3 major
conducting collaterals >1-2 mm. diameter," said Dr. Summers.

The study confirmed data previously presented at both the American College
of Cardiology and European Society of Cardiology in March and August last
year, respectively. Earlier mouse studies of the nicotine receptor agonist
demonstrated significant efficacy over both fibroblast growth factor (FGF)
and Del 1.

Therapeutic angiogenesis is the growth of new blood vessels and is
potentially a non-surgical "biological bypass" for patients with
cardiovascular disease (CAD). CAD usually blocks or narrows blood vessels
essential for limb circulation and heart function. More than 65 million
Americans suffer from some form of CAD (source AHA).

Endovasc Ltd., Inc. is a biopharmaceutical/biotech company pioneering
liposomal and stent drug delivery technology. The Company`s products and
processes are covered by patents and trade secrets for competing in a
multi-billion dollar market. The company owns the worldwide exclusive
license for the newly discovered angiogenesis agent, nicotine receptor
agonist.

The foregoing statements are made under the "Safe Harbor" Private Securities
Litigation Reform Act of 1995 and may contain forward-looking statements
that involve risks and uncertainties that may not be evident at the time of
this release. For more information about Endovasc Ltd., Inc., contact:

Barbara Richardson
Endovasc Ltd., Inc., 15001 Walden Road, Suite 108, Montgomery, TX 77356
Phone: [phone]; Fax: [phone]
Email: [e-mail]; Or visit our web site: www.endovasc.com

[[KERN]Codex]

Hallo

..und der Kurs hat auch gleich entsprechend reagiert:



Wir waren heute schon auf 0,4 Dollar!!

gruß codex

[EUWE]

Hallo,

Um die möglicherweise beträchtliche Kursrelevanz der
gestrigen Meldung bezüglich der Nicotine Receptor Agonist NRA Methode
von Endovasc einmal zu verdeutlichen,
sei hinzugefügt, dass die angesprochen Konkurrenzmethoden
a)Vascular Endothelial Growth Factor (VEGF) und
b)Fibroblast Growth Factor (FGF)
derzeit in klinischen Studien von Chiron bzw. Human Genome
Sciences(VEGF-2 Gene therapy) gescheitert bzw "on hold" sind.

P.S. Pipelinerecherche ist sehr gut auf http://www.recap.com "clinicals"

Regards

EUWE

[meisterspieler]

konnte momentan keine news ausfindig machen (wisst ihr vielleicht was??) die den rückgang von unserer endv erklären würden.
habe deswegen mal den chart studiert und sprech` mir eben selbst ein bisschen mut zu - also:
1: eine kleine unterstützung befindet sich bei 25 cent, die der kurs ja heute erreicht hat. entweder er prallt an ihr ab oder aber er will
2: den tiefststand von glaube ich 17 cent noch mal testen.
es ist eben geduld angesagt.
bei raging bull wird der wert relativ widersprüchlich eingeschätzt. einer postet, dass wir neue tiefststände von 5-10 cent sehen werden, ein anderer meint, dass es kein problem sein wird, 2-3 dollar zu erreichen und ein dritter behauptet, dass endv nicht mehr als 75 cent wert sei.
also, die wissen auch nicht mehr als wir...

[[KERN]Codex]

hallo

...leider weiß ich auch nicht so genau, warum ENDV so krass abfällt, aber bei 17 cent kaufe ich nach...HEHE

gruß codex

P.S. ist sowieso n zocker engagement!

[Kalifmann]

Land unter auf breitester Front, auch der Dow beginnt zu wackeln, offenbar hält nur Endovasc noch(?) die Fahne hoch,
für mich (EUWE) ein Zeichen einer nachhaltigen, "echten" Bodenbildung, man sollte doch möglicherweise bei 0,2 noch mal nachlegen, denn eines steht
doch fest und darüber gibt es meiner Meinung nach keinen Zweifel: Sollte Lirostin in absehbarer Zeit (ca.1-1,5 Jahre bei gesicherter Finanzierung) in die 3.Phase gelangen, ursprünglich wollte ENDV die ersten beiden Phasen "überspringen" was jedoch im NOV`99 von der FDA abgelehnt wurde, dann sollte die Pipeline von Endovasc zumindest im Vergleich zu anderen ca. $100 Mio. Börsenwert auf die Waagschale bringen........go for it?!

[SultanKhan]

Wer kennt sich aus und kann sagen was dieses Filing Form SC 13G/A (22. März 2001) zu bedeuten hat?

http://www.pinksheets.com/quote/news.jsp?url=fis_story.asp%3…

[[KERN]Codex]

hallo leutz

nachdem der kursverlauf nicht ganz so erfreulich war, kämpft sich endv in den letzten tagen wieder hoch--> und das nicht zu langsam!



...der MACD steht kurz vor einem Kaufsignal!

gruß Codex

0,2 cent sind noch drinn...jede wette

[SultanKhan]

Der mögliche Grund für den vermeintlich grundlosen Kursverfall könnte dieser sein:


Dated March 20, 2001 Form SB-2

ENDOVASC, LTD., INC.


The Offering

This prospectus relates to the possible sale of up to 21,924,108 shares of common stock.
The selling stockholders may sell all or any portion of the shares in this offering from time to time in one
or more transactions by a variety of methods, including through the Over the Counter Electronic Bulletin Board
or in negotiated private transactions. The selling stockholders will determine the selling price of their shares.

We are authorized to issue 100,000,000 shares of common
stock and 20,000,000 shares of preferred stock in one or
more series. As of March 1, 2001, there were 17,191,622
shares of common stock and 17,876 shares of preferred stock
issued and outstanding.

We will not receive any proceeds from the sale of the
common stock offered by the prospectus, except when
warrant holders choose to exercise their warrants, in which
case Vianet will receive the exercise price of the warrants.

@Kernkodex
Hör doch bitte auf (danke!) diesen Thread mit deinen
nervig-sinnlosen Chartbildchen vollzumachen, heh?
Get a clue, mähn!
Wer versteht dieses "Offering", wie können hier Insider/Institutions hier 21 Mio shares verkaufen,
wo doch nur 17 Mio "issued and outstanding" sind, vor allem aber wieso verdient Endovasc dabei nix....?,... Fragen über Fragen.

[[KERN]Codex]

hallo SultanKhan

erstens-> wenn du mit mir redest, dann schreib meinen namen mal richtig.
zweitens-> charts sinnlos?!
Charts gehören zu der Bewertung und i. allg. zu Erklärungen dazu, ob du es willst oder nicht. Wenn ich über irgendein Unternehmen Informationen heraussuche oder Infos präsentiere ,dann betrachte ich zuersteinmal den chart, denn der chart repräsentiert alle news, adhocs, usw. -verstehsde?
Also du bist der erste [ seit gut einem Jahr (auf w:0) ], der sich ueber charts aufregt...*lol*
Naja zu ENDV :

Aktuelle Daten 12.04.2001
Aktueller Kurs 0,17
Kurszeit 12.04., 21:38
Differenz +0,03 (+21,43%)
Geldkurs 0,165
Geld-Zeit 20:47, 12.04.
Geld-Volumen (St.) 5.000
Briefkurs 0,17
Brief-Zeit 20:47, 12.04.
Brief-Volumen (St.) 5.000

(q. comdirect)

naja diesmal EXTRA FUER DICH kein chart! - und freus dich?

gruß Codex

[SultanKhan]

Get a hold on yaself, geeez!
Vielleicht rege ich mich zu recht über die sinnlose Anhäufung ein und
desselben Chart auf, mein Gutster, da sich CODI Charts, wie du offenbar
noch nicht bemerkt zu haben scheinst, ja von selbst aktualisieren.
Dies` könnte potentiellen Neuinvestoren, die sich hier im Thread informieren wollen,
stattdessen aber nur eine eintönige Bildersammlung vorfinden, genauso ergehen. Mannomann!

[[KERN]Codex]

hey SultanKhan
FROHE OSTERN

Sicherlich habe ich bemerkt, dass sich die Charts von selbsd aktualisieren...*binjanichtbloed*
Immer schön locker und cool bleiben --> wozu gibbet denn smilies ?

gruß Codex

[SultanKhan]

Naja, also dann...
"Regnet`s auf die Osterglocken,
kann auch der Chart nix mehr verbocken."

[[KERN]Codex]

hehe

...aktuell endv von 0.1 auf 0.11 + 10%

[Chalifmann]

Endovasc +50% bei hohen Umsätzen


Es dürfte wohl in Kürze ein Newsletter oder ähnliches veröffentlicht werden,genaues weiss ich nicht,jedoch hat mir
Dr.Summers folgende mail kürzlich zukommen lassen:

Date: Thu, 12 Apr 2001 10:53:05 -0500
"Dear Herr .....
Mike Kuczkowski graciously forwarded your query to me in order to update straight "from the horse`s mouth" as we say in Texas.

Firstly, I want to assure you there will be no, I repeat, no pink-sheet listing for Endovasc. As long as we continue as a "fully reporting" company with the Securities Exchange Commission (SEC) we will continue to be carried by the National Association of Securities Dealers (NASD) Over The Counter (OTC) Bulletin Board daily real-time listing!

This requirement includes both quarterly and annual (audited) reports to the Commissioner. We intend to continue reporting.

Secondly, please assure your investors in Bielefeld that our company is sound in spite of the low stock valuations (Which, by the way offer an excellent buying opportunity to lower your average price per share) we continue to make excellent progress in getting into a revenue producing stage. As a matter of fact, we project that we will have something like US$ 700, 000. in revenues this year ending June 30, 2001. There is a real chance that we will have two products in the market as well, our Liprostin(tm) for critical limb ischemia, (a common artery disease causing poor blood circulation in the lower limbs, especially prevalent in the over 60 age group) Our angiogenesis drug NRA will also be in the clinic in Italy late this year! This new agent is a nicotine molecule that has extraordinary potential to stimulate new blood vessel growth in the heart that was lost some of its function due to poor blood supply from blocked coronary arteries. It has the potential reduce or eliminate the need for open-heart surgical by-pass.

Both drugs have market potential over US$ 1 billion.

:Unfortunately our stock has been somewhat manipulated by a couple of hedge funds during the current down-trend in the US stock market. This is about over and with some really good news on the way (This month or early May) I predict that you will see quick rise in the price of the stock.

I hope that your and your co-investors in Germany are in our stock for long term, not short term gains. If so, you have made a wise investment that will return many times your initial investment.

I thank you for voicing your concern to Michael. Please feel free to continue to ask for information or updates when you feel the need."

Most sincerely yours,

Dr. David Summers, FACA
Chairman & CEO


David P. Summers, Ph.D.
Endovasc Ltd., Inc.
15001 Walden Road, Suite 108
Montgomery, TX 77356
Ph: 936-448-2222 Fax: [phone]

[Chalifmann]

Ausserdem gibt es noch diese erfolgversprechende News, nämlich daß Liprostin
aufgrund guter Testergebnisse direkt von Phase1 in Phase3 warscheinlich wird übergehen können:

Monday May 7, 8:30 am Eastern Time

Press Release
Endovasc Announces Plans to Bypass Phase II Liprostin Clinical Trials and Proceed to Phase III
MONTGOMERY, Texas--(BW HealthWire)--May 7, 2001--Endovasc Ltd. Inc. (OTCBB:ENDV - news) today announced plans to move directly into Phase III human trials with Critical Limb Ischemic patients.

Having demonstrated very successful results from the recently concluded animal studies as well as a significant safety profile in Phase I human trials in healthy volunteers, Endovasc Ltd. Inc. has determined it will proceed with Phase III, i.e., the last phase of IND clinical development, as recommended by the Food and Drug Administration at their October 1999 Pre-Investigational New Drug Application (Pre-IND) meeting.

``When our Investigational New Drug (IND) application was originally submitted to the FDA, Endovasc Ltd. Inc. was granted a waiver by the FDA to forego Phase I & II clinical trials and proceed to Phase III, on the condition that the trial would include additional placebo arms,`` said Dr. David P. Summers, chairman and CEO. ``In July 2000, the Company decided that to ensure success of Phase III trials a dose-titration modified Phase I/II trial would be conducted to determine the safe dosing regimen.``

``Now,`` says Dr. Summers, ``with our successful animal studies and human trial results in Phase I, we can bypass Phase II and go directly into Phase III. I feel confident that we`ll be able to meet our target date for treating the first patient in Phase III in November of this year.``

Dr. Lorenz Hofmann, Endovasc`s Regulatory Affairs and Clinical Operations consultant, announced that the Phase III protocol is ready for submission to the FDA. Site selection and investigator enrollment is continuing. ``Pending the approval of the Phase III protocol by the FDA, the company`s plans for testing on Critical Limb Ischemic patients will begin early in November. The patients in the study are prime candidates to prove the efficacy of our drug, Liprostin(TM), having no option other than a repeat re-vascularization procedure or amputation of the lower limbs and extremities. These pessimistic outcomes are the result of long-term Diabetes and/or Peripheral Artery Disease (PAD),`` according to Dr. Hofmann.

Critical Limb Ischemia is caused by the occlusion of blood vessels in the lower limbs and extremities, preventing oxygenated blood flow to the affected areas. Eventually, gangrene results and the only option to save the patient`s life is amputation. The use of Endovasc`s signature drug, Liprostin(TM) (PGE-1), a powerful vasodilator and stimulator for new blood vessel growth, will aid in the process of keeping the vessels open and receptive to healthy blood flow.

Endovasc Ltd. Inc. is a biopharmaceutical/biotech company pioneering liposomal drug delivery technology. The Company`s products and processes, including Liprostin(TM) (liposomal encapsulated PGE-1), are NRA (Nicotine Receptor Agonist, an angiogenesis agent), stent/medical device coating technology, and a biodegradable/resorbable stent. All are covered by patents and trade secrets for competing in a multi-billion dollar market.

The foregoing statements are made under the ``Safe Harbor`` Private Securities Litigation Reform Act of 1995 and may contain forward-looking statements that involve risks and uncertainties that may not be evident at the time of this release.


--------------------------------------------------------------------------------
Contact:

Endovasc Ltd. Inc., Montgomery
Jack Sorbi, 936/448-2222
Fax: [phone]
[e-mail]
www.endovasc.com

[[KERN]Codex]

hey chalifman

danke nochmal fuer die news
der kursverlauf von endv war ja gestern sehr erfreulich *gg*
hoffe, dass es heute weitere Impulse gibt - ist auch wahrscheinlich...

gruß Codex

[[KERN]Codex]

hallo

meine bios gehen heute ja echt ab!! erst xoma und nun endovasc => womit hab ich das verdient?! *hehe*



endv aktuell 26,17% im plus

gruß Codex

[[KERN]Codex]

endovasc startet total durch und liegt derzeit satte 35% im plus

[Chalifmann]

Erneuter Anlauf von ENDV, wird es diesmal klappen....

Wednesday May 23, 8:30 am Eastern Time

Press Release
Endovasc Brings On Dr. Lorenz Hofmann to Speed Approval of Liprostin
MONTGOMERY, Texas--(BW HealthWire)--May 23, 2001--Endovasc Ltd. Inc. (OTCBB:ENDV - news) today announced the addition of one of the country`s leading consultants in Clinical and Regulatory Affairs for drug development, Lorenz Hofmann, Ph.D. to its clinical regulatory staff.

``The addition of Dr. Hofmann to our staff adds great experience and knowledge to Endovasc`s upcoming Phase III Clinical Trial that is scheduled to begin in November,`` said Dr. David P. Summers, chairman & CEO of Endovasc. ``Larry Hofmann was brought on in order to assure our commitment to that deadline.``

The Company stated Endovasc`s Liprostin(TM) Phase III trial will be directed to the treatment of Critical Limb Ischemia, caused by the occlusion of blood vessels in the lower limbs and extremities, preventing oxygenated blood flow to the affected areas. Eventually, the disease deteriorates to gangrene and the only option to save the patient`s life is amputation. Liprostin(TM) (Prostaglandin E-1) is a powerful vasodilator and angiogenic agent and should aid in the process of keeping the vessels open and receptive to healthy blood flow, and maintain the limb.

Dr. Hofmann has a Ph.D. in Cardiovascular-renal pharmacology and has more than 20 years experience in clinical research at the Director and Associate Director levels with major pharmaceutical and medical device companies including: Ross/Abbott Labs, Adria Labs, Parke-Davis and Schwarz Pharma. Dr. Hofmann`s credentials include all areas of product development, clinical research and regulatory affairs, such as medical monitor, Investigational New Drug (IND) applications/New Drug Applications (NDA) project leader, Food & Drug Administration negotiations for 15 INDs, 8 approval NDAs for marketed drugs and several medical devices. ``Is it any wonder we selected Dr. Hofmann?`` asked Dr. Summers.

Endovasc Ltd. Inc. is a biopharmaceutical/biotech company pioneering liposomal drug delivery technology. The Company`s products and processes, which include Liprostin(TM) (liposome encapsulated PGE-1), NRA (Nicotine Receptor Agonist, angiogenesis agent), stent-coating technology and a biodegradable/resorbable stent, are covered by patents and trade secrets for competing in a multi-billion dollar market.

The foregoing statements are made under the ``Safe Harbor`` Private Securities Litigation Reform Act of 1995 and may contain forward-looking statements that involve risks and uncertainties that may not be evident at the time of this release.

P.S Kernkodex,
Du kannst es nicht lassen mit deinen Charties, stimmts? Es ist eine Sucht. Naja, für heute sei dir vergeben, Hauptache du arbeitest dran und machst Fortschritte. Hast du unter 10 Cent ordentlich nachlegen können? Ist mir nicht gelungen, Mist, obwohl ich es versucht hatte und 9 Cent ja auch erreicht wurden, aber dennoch bei mir nicht bedient wurden........

[[KERN]Codex]

@chalifmann

das hasde mal wieder sehr gut ausgedrückt *hihi* ja es scheint eine sucht zu sein - danke fuer den hinweis (wenn es sogar dir auffällt, wird es wohl stimmen) => ich arbeite drann *versprochen*
naja leider konnte ich unter 0,1$ nur einmal fuer wenig geld nachlegen, aber heute habe ich mich leider nicht dazu gerungen - was solls..!?
mal gucken wie weit diesmal der zug fährt...

thx nochmal fuer die news...

gruß Codex

p.s. kauft xoma *gg*

[Robin7]

Related Quotes

ENDV.OB
0.16
+0.01

delayed 20 mins - disclaimer



ADVERTISEMENT


Friday June 1, 8:30 am Eastern Time
Press Release
Endovasc Presents Drug Delivery Poster At Interventional Cardiovascular Therapeutics II Meeting June 16-17
Presentation in Athens to Medical Community Highlights Progress on Endovasc`s Stent-Coating Technology
MONTGOMERY, Texas--(BW HealthWire)--June 1, 2001-- Endovasc Ltd. Inc. (OTCBB:ENDV - news) today announced a presentation will be made in Athens, Greece, on the Company`s stent-coating technology developed in its laboratory in Montgomery, Texas. Endovasc Ltd. Inc., a pioneer in drug delivery technology that targets patients with cardiovascular and peripheral limb ischemia, is advancing daily in the development of the definitive stent coating to deliver therapeutic agents to a wound site over an extended period of time.

According to Dr. David Summers, CEO and spokesperson for Endovasc, ``We have developed a unique coating technique containing Prostaglandin E-1 (PGE-1) that we are applying to metal stents. When deployed in an artery, the coated stent provides the slow release of microgram quantities of the drug which should reduce or prevent re-blockage of the vessel. We are very excited about its future!``

Stents are tiny mesh tubes that are implanted into a blood vessel and serve as scaffolding to keep vessels open following surgery or angioplasty. Despite their utility, stents have been plagued by re-blockage (restenosis) and occlusion due to thrombosis. Re-blockage results from the migration of vascular smooth muscle cells through a break in the endothelial lining of the vessel wall.

Prostaglandin E-1 (PGE-1) is a naturally occurring, chemically related fatty acid, which has shown to be a potent vasodilator, platelet inhibitor and anti-thrombotic. ``We chose PGE-1 because of its ability to block smooth muscle cell migration and prevent platelet aggregation, which can lead to the formation of blood clots,`` said Dr. Summers.

Endovasc`s Director of Research and Development, Dr. Diane Dottavio, stated that, ``Unlike other drugs now being tested as anti-restenosis agents, PGE-1 has a very short half-life, about 90 seconds, and is not cytotoxic, even at levels 100 times higher than the dose required to block migration. This is a tremendous advantage in the FDA approval process.``

Endovasc`s research team, under the supervision of Dr. Dottavio, has demonstrated, in vitro under physiological conditions, prolonged release of PGE-1 from coated stents.

Endovasc Ltd. Inc. is a biopharmaceutical/biotech company pioneering liposomal drug delivery technology. The Company`s products and processes, which include Liprostin(TM) (liposome encapsulated PGE-1), NRA (Nicotine Receptor Agonist, angiogenesis agent), stent-coating technology and a biodegradable/resorbable stent, are covered by patents and trade secrets for competing in a multi-billion dollar market.

The foregoing statements are made under the ``Safe Harbor`` Private Securities Litigation Reform Act of 1995 and may contain forward-looking statements that involve risks and uncertainties that may not be evident at the time of this release. For more information about Endovasc Ltd. Inc., contact:


Investor Relations: John (Jack) T. Sorbi, [e-mail]
Clinical Research: Barbara J. Richardson, [e-mail]

Endovasc Ltd. Inc.
15001 Walden Road, Ste. No. 108
Montgomery, TX 77356
Phone: [phone]
Fax: [phone]
Web: www.endovasc.com



--------------------------------------------------------------------------------
Contact:
Endovasc Ltd. Inc., Houston
John (Jack) T. Sorbi, 936/448-2222
[e-mail]
or
Barbara J. Richardson, 936/448-2222
[e-mail]

[Robin7]

Kann jemand von den schon länger Investierten in ein
paar kurzen Sätzen beschreiben was von ENDV eigentlich
entwickelt wird. Danke.

[[KERN]Codex]

hallo

hier nochmal der link zu der erläuterung (verfasst von puhvogel) bezüglich des geschätsfeldes von endovasc, fuer alle die es sonst noch interessiert...

Thread: Endovasc gestern +42%...heute geht die Reise weiter!!

gruß Codex

[[KERN]Codex]

ENVC zuletzt wieder knapp 30% hoch! Kurs 1.12
Nachbörslich geht es leicht runter (1.095)



mit hohen Umsätzen geht es wieder ueber die 1 Dollar =)




Patente ab 2000:


07/09/2002 – Nicotine in Therapeutic Angiogenesis and Vasculogenesis
The invention features methods for induction of angiogenesis by administration of nicotine or other nicotine receptor agonist. Induction of angiogenesis by the methods of the invention can be used in therapeutic angiogenesis in, for example, treatment of ischemic syndromes such as coronary or peripheral arterial disease.

05/28/2002 – Prosthesis with Biodegradable Surface Coating and Method for Making Same
The invention provides a prosthesis coated with a biodegradable, resorbable and biocompatible surface coating.

02/08/2001 – Nicotine Receptor Agonists in Stem Cell and Progenitor Cell Recruitment
The invention features methods for recruitment of bone marrow-derived stem cells (e.g., endothelial cell precursors, hematopoietic stem cells) by administration of nicotine or other nicotine receptor agonist. The methods of the invention can be used in, for example, treatment of conditions amenable to treatment by recruitment of bone marrow-derived stem cells (e.g., neutropenia).

06/27/2000 – Method for Making a Stent
The stent of the invention comprises a coil including a plurality of arcuate sections that alternate clockwise and counterclockwise directions around a central longitudinal axis. Each arcuate section includes a pair of curved turns joined by a cusp.



LESEN!!

Endovasc is currently the only OTCBB-listed company with two major potential cardiovascular blockbuster drugs approved for Phase III trials. Endovasc`s revolutionary new nicotinic acetylcholine receptor (AChR) agonist, ANGIOGENIX(TM) treatment has shown to recruit the body`s own stem cells that help grow new heart vessels to relieve chest pain and improve heart function. The company`s liposomal prostaglandin-based treatment, Liprostin(TM), may prevent restenosis (re-blockage of arteries), increase circulation, and reduce leg pain due to poor blood flow. Both of these cardiovascular drugs have been approved for final FDA Phase III human clinical trials.

In the interview with BioBN
-->BioBusiness Networks - a media organization focusing on providing information for investors in the healthcare and biotechnologies industries. Other featured companies include Millennium Pharmaceutical and Invacare Corporation<--
, Dr. Summers discusses the company`s future and specifically, the company`s plans for entering the revenue-generating phase of its business model. According to Summers, there are several factors that may dramatically increase Endovasc`s profitability in the future.

First, upon entering Phase III trials, biotech companies can start making money even though their drugs are not yet on the market. When the first positive results from their human trials start to come in, companies can start selling sub-licensing agreements and rights to their drugs to major pharmaceutical companies. These upfront fees can be significant, from millions to literally billions of dollars. Biotech companies can also sell distribution rights for their products. In Endovasc`s case, the upfront fees could be significant because the company`s drugs focus on the vast cardiovascular and metabolic markets, accounting for more than $69 billion in sales volume per year - 25% of the entire pharmaceutical market.

Cardiovascular diseases are the number one cause of death in the western world today.They account for 50% of deaths worldwide, nearly double of those caused by cancer, the second most prevalent cause of death. It is estimated that in the United States alone, the economic cost of cardiovascular diseases is over $250 billion per year. `

Secondly, Endovasc has created a new subsidiary called Nutraceutical Development Corporation (NDC) for its potential blockbuster nonprescription products. The company believes that its ANGIOGENIX(TM)-based and other nAChR agonist nutraceuticals, which combined with high protein/mineral complexes, could become blockbuster nonprescription products, producing positive cash flow even sooner than its later stage drugs because they are not subject to the FDA approval process. The current U.S. market size for nutraceuticals is estimated to be approximately $28 billion annually.

Hat sich viel getan in letzter Zeit =)


Die letzten News:

+++Monday October 28, 2002+++

Cardinal Health Speeds Delivery of Endovasc`s Amazingly Safe New Heart Drug - To Be Used to Grow New Blood Vessels After Heart Attack
7:10 am - Business Wire
Columbia University Test Results: Endovasc`s Novel Angiogenic Treatment Is Safe - Studies Suggest Improved Blood Flow By Growth of New Blood Vessels to Ischemic Hearts
7:07 am - Business Wire

+++Friday October 25, 2002+++

Endovasc Announces Its Plans for Amex Listing
6:30 am - Business Wire

+++Wednesday October 23, 2002+++

Endovasc - Company Behind a Revolutionary Treatment That May Grow New Human Heart Vessels - Expands on its Future Plans on Wall Street.Net
9:03 am - Business Wire
Leading GNC Vendor to Invest $2.5 Million in Developing Nutraceutical Products Based on Endovasc`s Technologies
7:01 am - Business Wire

+++Monday October 21, 2002+++

Endovasc Ltd. Inc.: Cardinal Health To Formulate Revolutionary New Heart Drug
5:50 am - Business Wire
Cardinal Health to Formulate Revolutionary Cardiovascular Drug
5:50 am - Business Wire


Viel Spaß beim investieren

Gruß codex

[desastermaster]

Aber zu bedenken bleibt, dass die Altaktionaere von den
Genossen officers and directors eiskalt enteignet worden sind.
Siehe hierzu das folgende posting von user NEOE
best
dm

Bitte lies dir dieses Posting genau durch und sag mir ehrlich was man von dieser Company halten soll.
So schön sich das alles anhört (ich bezweifle auch nicht die Qualität der Medikamente) , hier wird kräftig abgezockt.


Aufgrund der Tatsache , daß unser Herr "Merril Lynch Analyst=EndovascCEO" sich weit nach dieser Abmachung
noch über die lächerliche MarketCap beschwert hat , grenzt an eine bodenlose
Frechheit. Bitte folgende Passage lesen , aus einem Sec-Filing (10/17/2002), dass verständlicherweise so
versteckt wie möglich gehalten wurde:

As of June 30, 2002, certain officers and directors of the Company exchanged 17,779,083 shares of their
common stock for 1,777,908 shares of Series B convertible preferred stock, which
included preferential voting rights of 500 times those attributable to common stockholders. The right to
convert common stock to Series B convertible preferred stock was offered only to certain
common stockholders, including officers and directors of the Company. Such stockholders, officers
and directors, who were selectively and preferentially offered Series B convertible preferred
stock, avoided a 97.5% dilution of their position as common stockholders that all other common
stockholders experienced. Effective July 9, 2002, upon reincorporation of the Company in the state
of Delaware, and subsequent to the 40 to 1 reverse split of common stock, the officers` and directors`
Series B preferred stock was automatically converted back to 17,779,083 shares of the
Company`s common stock.

Die Dilution von rund 2 Millionen Shares auf nun ca. 34 Millionen ist übrigens vonstatten gegangen ,
ohne der Company auch nur einen Cent ihrer Schulden vom Buckel zu nehmen.
Rekordverdächtig. Und der Split wurde wohl einfach durch die erhöhte voting-power gerechtfertigt.


Und es geht weiter:
Der CEO spricht von Einnahmen von 100 Millionen (Bereich Nutraceuticals) im nächsten Jahr , das
bei einem Partner (GNC)der dieses Jahr vermutlich!! 50 Millionen an Einnahmen hat und
Endovasc lediglich 10 Prozent an Lizenzgebühren bezahlt. Also bräuchte man wohl 1 Milliarde an
Einnahmen im ersten Jahr. In Zahlen: 1,000,000,000 Dollar!!!!
Zudem gibt es nichts weiter als einen Letter Of Intent mit GNC , der CEO redet aber , als wäre
schon alles in trockenen Tüchern und erwähnt dies alles explizit als Vorraussetzung für das
AMEX-Listing.

NA DENN PROST MEINE HERREN.

[desastermaster]

Die dynamik bei ENVC ist aber schon erstaunlich
erster $1.67 +90%
best
dm

[desastermaster]

Hier noch die zugehoerigen news:
best
dm

Press Release for Endovasc Ltd Inc


Columbia University Test Results: Endovasc`s Novel
Angiogenic Treatment Is Safe - Studies Suggest
Improved Blood Flow By Growth of New Blood Vessels
to Ischemic Hearts
10/28/2002 7:04:00 AM
100% Of Four Different Animal Species Demonstrated
Signs of New Vascular Growth; Human Patients to Be
Treated Soon

MONTGOMERY, Texas, Oct 28, 2002 (BUSINESS WIRE) -- Endovasc Ltd., Inc. (ENVC) announced today
very positive end-point findings of its animal studies and results of its latest pig study conducted at Columbia
University for the company`s ANGIOGENIX(TM) heart treatment - already approved for the final Phase III FDA
human clinical trials. ANGIOGENIX(TM) is a simple, small molecule derived from the tobacco plant that, when
given in low doses, has demonstrated remarkable results in stimulating robust growth of new vessels in four
different animal experiments with simulated blood-flow deficiencies, suggesting that it will do the same in a
human patient`s heart and limbs.

According to the Company, EVERY test animal group demonstrated safety and angiogenesis (new blood
vessels) at the effective dose with no observable side effects. This means that upon completing the Phase III
human trials, ANGIOGENIX(TM) could provide relief for millions of Americans suffering from fatigue and
relentless chest pain (angina) caused by severely and chronically blocked coronary arteries, or obstructed
peripheral vascular limbs making walking more than a few steps extremely painful. The treatment could
become publicly available within 18-24 months if early human results of 75 patients provide sufficient proof to
enable the FDA to give fast-tract approval, providing many heart attack and ischemic limb victims the option of
a painless and effective alternative for bypass surgery.

In Columbia`s latest study, the report stated: "Columbia University conducted an uncontrolled preliminary
feasibility study in which low-dose nicotine was injected into chronic ischemic porcine myocardium. In this
study of five pigs, test animals underwent ameroid constriction placement on the circumflex artery and were
tested for intramyocardial effects of nicotine after induced ischemia was demonstrated in the target zone of the
myocardium. The focus of the study was on measurement of myocardial perfusion at baseline and at about
five weeks after nicotine injections.

"The data showed some improvement in subendocardial perfusion in 3 of the pigs and in epicardial perfusion in
2 of the pigs. Histological evaluation showed evidence of DNA synthesis (BrdU) in relatively large vessels near
injection sites, consistent with vascular growth. Different than observed with direct intramyocardial injections of
other growth factors, there were no large regions of fibrosis or inflammation noted at the injection sites. There
were no obvious adverse effects observed during the injections or the follow-up period."

"In plain English, this study means that our drug simply works, and it is safer and works better than anything
else on the horizon for angiogenesis. The injection sites were clearly delineated by trichrome staining of
endothelial and smooth muscles cells, around large areas of unmistakable vascular voids. But of interest, we
saw BrdU incorporation of DNA at considerable distance from the injection sites, which one might speculate
could be evidence of lymphangiogenesis, new capillary formation, or de novo transdifferentiation of bone
marrow stem cells," said Chairman and CEO of Endovasc, Dr. David P. Summers.

"Furthermore, ANGIOGENIX(TM) works by simple injection, binding the acetylcholine receptors (nAChR) on
endothelial cells and activating DNA synthesis of growth factors of the angiogenic cascade. This novel
pathway was unknown until recently discovered at Stanford University, and involves processes quite different
than our competitors` use of transfection viruses as vectors. We think it is safer and believe we have at least a
3-5-year lead on our nearest competitors," he said.

Endovasc`s ANGIOGENIX(TM) treatment is currently the only viable angiogenesis treatment approved for
Phase III trials. The company is well ahead of all other biotech firms in bringing an angiogenesis drug to the
market. The company`s larger competitors, Genentech (DNA) and Genzyme (GENZ) are still in Phase II trials
with their angiogenesis treatments and are experiencing various challenges, whereas Endovasc`s treatment
has already been approved for FDA Phase III human clinical trials.

In earlier studies, performed at Stanford University, researchers used a regional chronic ischemia model in both
the mouse and the rabbit. In those tests, a same dose of ANGIOGENIX(TM) produced angiogenesis and
reperfusion recovery by new blood vessels as well as a four-fold increase in stem cell recruitment and
mobilization in the parabiotic mouse marked with LacZ and endothelial progenitor cell (EPC) markers for CD 31
receptors. ANGIOGENIX(TM) was discovered at Stanford University. The United States Patent No. 6,417,205,
"Nicotine in Therapeutic Angiogenesis and Vasculogenesis," was issued to Stanford on July 9, 2002. Stanford
has licensed Endovasc the exclusive worldwide rights to nicotine field of use in angiogenesis and
vasculogenesis. Additionally, Endovasc has an exclusive option on PCT WO 01/08683-A1 titled "Nicotine
Receptor Agonist in Stem Cell and Progenitor Cell Recruitment."

The U.S patent enjoys a patent protection until 2022. The grant of the patent to Stanford provides broad patent
rights. By right of its worldwide exclusivity, Endovasc can fully negotiate sublicenses, distribution, and other
rights with companies and other interested parties.

Cardiovascular and metabolic markets account for more than USD 69 billion in sales volume per year - 25% of
the entire pharmaceutical market. Cardiovascular diseases are the number one cause of death in the western
world today. They account for 50% of deaths worldwide, nearly double of those caused by cancer, the second
most prevalent cause of death. It is estimated that in the United States alone, the economic cost of
cardiovascular diseases is over USD 250 billion per year.

Press Release for Endovasc Ltd Inc


Cardinal Health Speeds Delivery of Endovasc`s
Amazingly Safe New Heart Drug - To Be Used to Grow
New Blood Vessels After Heart Attack
10/28/2002 7:10:00 AM
MONTGOMERY, Texas, Oct 28, 2002 (BUSINESS WIRE) -- Endovasc Ltd. Inc. (ENVC) - a biotechnology
company with two potential $1 billion dollar blockbuster cardiovascular drugs approved for final FDA Phase III
human trials - announced today that Cardinal Health (CAH) is one month ahead of the original schedule in its
process of formulating the ANGIOGENIX(TM) drug according to cGMP FDA standards.

Cardinal Health has substantiated the validation process for two of the three doses to be formulated,
previously done at the University of Kentucky, therefore eliminating the need for repeat validation. This should
cut 4-5 weeks off of the completion of the project, making the ANGIOGENIX(TM) drug available sooner than
originally anticipated. ANGIOGENIX(TM) is the revolutionary new treatment that has shown to recruit the
body`s own stem cells that help grow new blood vessels predicted to relieve chest pain and improve heart
function in patients with chronic myocardial ischemia. According to Endovasc, approximately 750,000 U.S.
patients could be treated for this condition every year.

Cardinal Health, Inc. - with over $51 billion in sales, and a market capitalization of almost $30 billion - is a
leading provider of products and services to healthcare providers and manufacturers, helping them improve the
efficiency and quality of healthcare.

Endovasc should already begin receiving the first ANGIOGENIX(TM) drugs in December. The company is
currently evaluating the possibility of starting an FDA pilot trial with one of the doses immediately upon receipt
of that formulated drug. This would provide an opportunity for five human patients with no other treatment
options left to be treated with ANGIOGENIX(TM). The pilot study would be performed for compassionate
reasons only, and even though it could provide valuable data for Endovasc, it would not be part of the final
FDA Phase III human clinical trials.

Cardiovascular and metabolic markets account for more than USD $69 billion in sales volume per year -- 25%
of the entire pharmaceutical market. Cardiovascular diseases are the number one cause of death in the
Western world today. They also account for 50% of deaths worldwide, nearly double of those caused by
cancer, the second most prevalent cause of death. It is estimated that in the United States alone, the
economic cost of cardiovascular diseases is over USD $250 billion per year. Endovasc has two potential
blockbuster cardiovascular drugs approved for final FDA Phase III human clinical trials.

Recent experiments suggest that the company`s ANGIOGENIX(TM) treatment can stimulate the process of
angiogenesis and recruit the body`s own stem cells to spur the growth of new heart vessels predicted to relieve
chest pain and improve heart function. The company`s other late stage drug, Liprostin(TM), is a liposomal
prostaglandin-based treatment that studies suggest will prevent restenosis (re-blockage of arteries), thus
increasing blood circulation, preventing clotting, and reducing leg pain by increasing the oxygen and nutrients in
increased blood flow.

Endovasc`s products include ANGIOGENIX(TM), the revolutionary new treatment that has shown to recruit the
body`s own stem cells that help grow new blood vessels predicted to relieve chest pain and improve heart
function in patients with chronic myocardial ischemia; Liprostin(TM), a liposomal prostaglandin-based treatment
that studies suggest may prevent restenosis (re-blockage of arteries), increase circulation, and reduce leg pain
in patients due to poor blood flow from vascular disease. Additionally, the company has biodegradable stents,
drug-delivery stents and newly discovered nutraceutical applications that may accelerate therapeutic muscle
development (stroke, muscular dystrophy diseases, etc.) and quality-of-life for people seeking to increase
muscle mass. Another product using prostaglandin E-1 (PGE-1) precursor will be produced as a dietary
supplement for obesity and insulin control in overweight diabetic women.

[[KERN]Codex]

Es gibt Ergebnisse der aktuellen Studien und der Kurs explodiert förmlich
*hab gestern noch viel spass beim investieren gewünscht!*

gruß codex